BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 29593010)

  • 1. Differences in Breast Cancer Survival by Molecular Subtypes in the United States.
    Howlader N; Cronin KA; Kurian AW; Andridge R
    Cancer Epidemiol Biomarkers Prev; 2018 Jun; 27(6):619-626. PubMed ID: 29593010
    [No Abstract]   [Full Text] [Related]  

  • 2. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
    Press DJ; Miller ME; Liederbach E; Yao K; Huo D
    Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
    Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype.
    Vaz-Luis I; Lin NU; Keating NL; Barry WT; Lii H; Winer EP; Freedman RA
    Breast Cancer Res Treat; 2015 Jun; 151(3):697-707. PubMed ID: 26022349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.
    Tao L; Chu L; Wang LI; Moy L; Brammer M; Song C; Green M; Kurian AW; Gomez SL; Clarke CA
    Cancer Causes Control; 2016 Sep; 27(9):1127-38. PubMed ID: 27496200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors.
    Parise CA; Caggiano V
    Breast Cancer Res Treat; 2017 Oct; 165(3):743-750. PubMed ID: 28689363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.
    Li X; Yang J; Krishnamurti U; Huo L; Ward KC; O'Regan R; Peng L
    Clin Breast Cancer; 2017 Aug; 17(5):356-366. PubMed ID: 28576631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women.
    Keegan TH; Press DJ; Tao L; DeRouen MC; Kurian AW; Clarke CA; Gomez SL
    Breast Cancer Res; 2013; 15(5):R95. PubMed ID: 24131591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study.
    Tao L; Gomez SL; Keegan TH; Kurian AW; Clarke CA
    Cancer Epidemiol Biomarkers Prev; 2015 Jul; 24(7):1039-45. PubMed ID: 25969506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
    Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
    Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
    Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
    Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of breast cancer subtypes and survival among Hispanic women with invasive breast cancer in California.
    Banegas MP; Tao L; Altekruse S; Anderson WF; John EM; Clarke CA; Gomez SL
    Breast Cancer Res Treat; 2014 Apr; 144(3):625-34. PubMed ID: 24658879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
    Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
    World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population-based analysis of breast cancer incidence and survival by subtype in Ontario women.
    Seung SJ; Traore AN; Pourmirza B; Fathers KE; Coombes M; Jerzak KJ
    Curr Oncol; 2020 Apr; 27(2):e191-e198. PubMed ID: 32489268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
    Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
    Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
    Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
    Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor subtypes and survival in male breast cancer.
    Leone J; Freedman RA; Lin NU; Tolaney SM; Vallejo CT; Leone BA; Winer EP; Leone JP
    Breast Cancer Res Treat; 2021 Aug; 188(3):695-702. PubMed ID: 33770314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.
    Darlix A; Griguolo G; Thezenas S; Kantelhardt E; Thomssen C; Dieci MV; Miglietta F; Conte P; Braccini AL; Ferrero JM; Bailleux C; Jacot W; Guarneri V
    J Neurooncol; 2018 Jun; 138(2):369-382. PubMed ID: 29488184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.